Drug Profile
Superoxide dismutase liposomal - Redoxe
Alternative Names: APN-201; Liposomal recombinant human Cu/Zn-superoxide dismutase; Lipoxysan; rhSOD - RedoxeLatest Information Update: 07 Jan 2022
Price :
$50
*
At a glance
- Originator Polymun Scientific
- Developer Apeiron Biologics; Polymun Scientific
- Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Oxidoreductases
- Mechanism of Action Superoxide dismutase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Peyronie's disease; Radiodermatitis
Most Recent Events
- 27 Jul 2015 No recent reports on development identified - Phase-II for Radiodermatitis (Prevention) in Austria (Topical)
- 12 Mar 2013 Efficacy and adverse events data from a phase I/II trial in Radiodermatitis (Prevention) released by Apeiron Biologics
- 23 Jan 2012 Apeiron Biologics initiates enrolment in a phase Ib/II trial for Radiodermatitis (Prevention) in Austria (NCT01513278)